Experienced in Myositis

Michal P. Jakubaszek

Warsaw, MZ, PL 
Experienced in Myositis
Warsaw, MZ, PL 
OverviewLocationsClinical Research

Overview

Michal Jakubaszek practices in Warsaw, Poland. Jakubaszek is rated as an Experienced expert by MediFind in the treatment of Myositis. Their top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Myositis, and Synovitis.

Their clinical research consists of co-authoring 8 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Myositis.

Locations

Warsaw, MZ, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
View 1 Less Clinical Trial

8 Total Publications

Anti-citrullinated protein antibodies may be prognostic factor for vascularization of the synovial membrane in patients with high activity of RA.
Anti-citrullinated protein antibodies may be prognostic factor for vascularization of the synovial membrane in patients with high activity of RA.
Journal: Rheumatology international
Published: March 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Jakubaszek's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile